Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Brii Bio Announces Positive Interim Results for Hepatitis B Therapeutic Vaccine

publication date: Sep 6, 2023

Beijing Brii Biosciences reported positive topline results from an interim analysis of its first-in-class Pre-S1/Pre-S2/S therapeutic vaccine as a therapy for hepatitis B (HBV). BRII-179 is a novel recombinant, protein-based HBV immunotherapeutic designed to induce enhanced, broad B-cell and T-cell immunity. In 2019, Brii originally signed a $128.5 million agreement with VBI Vaccines of Boston for China rights to the therapeutic vaccine, but then in July of this year, it expanded the rights to global in a $437 million deal. More details....

Stock Symbol: (HK: 2137)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital